Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase

Mod Pathol. 2010 Jun;23(6):844-55. doi: 10.1038/modpathol.2010.60. Epub 2010 Mar 12.

Abstract

Serous tubal intraepithelial carcinoma (STIC) has been proposed as a precursor for many pelvic high-grade serous carcinomas. Our previous analysis of the ovarian cancer genome identified several genes with oncogenic potential that are amplified and/or overexpressed in the majority of high-grade serous carcinomas. Determining whether these genes are upregulated in STICs is important in further elucidating the relationship of STICs to high-grade serous carcinomas and is fundamental in understanding the molecular pathogenesis of high-grade serous carcinomas. In this study, 37 morphologically defined STICs were obtained from 23 patients with stage IIIC/IV high-grade serous carcinomas. Both STICs and the high-grade serous carcinomas were analyzed for expression of Rsf-1 (HBXAP), cyclin E, fatty acid synthase (FASN) and mucin-4. In addition, they were examined for expression of established markers including p53, Ki-67 and p16. We found that diffuse nuclear p53 and p16 immunoreactivity was observed in 27 (75%) of 36 and 18 (55%) of 33 STICs, respectively, whereas an elevated Ki-67 labeling index (>or=10%) was detected in 29 (78%) of 37 STICs. Cyclin E nuclear staining was seen in 24 (77%) of 35 STICs, whereas normal tubal epithelial cells were all negative. Increased Rsf-1 and FASN immunoreactivity occurred in 63%, and 62% of STICs, respectively, compared with adjacent normal-appearing tubal epithelium. Interestingly, only one STIC showed increased mucin-4 immunoreactivity. Carcinomas, when compared with STICs, overexpressed p16, Rsf-1, cyclin E and FASN in a higher proportion of cases. In conclusion, STICs express several markers including Rsf-1, cyclin E and FASN in high-grade serous carcinomas. In contrast, mucin-4 immunoreactivity either did not change or was reduced in most STICs. These results suggest that overexpression of Rsf-1, cyclin E and FASN occurs early in tumor progression.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Carcinoma in Situ / chemistry*
  • Carcinoma in Situ / enzymology
  • Carcinoma in Situ / pathology
  • Cyclin E / analysis*
  • Cyclin-Dependent Kinase Inhibitor p16 / analysis
  • Fallopian Tube Neoplasms / chemistry*
  • Fallopian Tube Neoplasms / enzymology
  • Fallopian Tube Neoplasms / pathology
  • Fatty Acid Synthase, Type I / analysis*
  • Female
  • Humans
  • Ki-67 Antigen / analysis
  • Mucin-4 / analysis
  • Neoplasms, Cystic, Mucinous, and Serous / chemistry*
  • Neoplasms, Cystic, Mucinous, and Serous / enzymology
  • Neoplasms, Cystic, Mucinous, and Serous / pathology
  • Nuclear Proteins / analysis*
  • Ovarian Neoplasms / chemistry*
  • Ovarian Neoplasms / enzymology
  • Ovarian Neoplasms / pathology
  • Trans-Activators / analysis*
  • Tumor Suppressor Protein p53 / analysis

Substances

  • Biomarkers, Tumor
  • Cyclin E
  • Cyclin-Dependent Kinase Inhibitor p16
  • Ki-67 Antigen
  • MUC4 protein, human
  • Mucin-4
  • Nuclear Proteins
  • RSF1 protein, human
  • TP53 protein, human
  • Trans-Activators
  • Tumor Suppressor Protein p53
  • FASN protein, human
  • Fatty Acid Synthase, Type I